To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients. To evaluate the necessity, efficacy, and safety of IV maintenance foscarnet therapy in preventing recurrent disease. To confirm the pharmacokinetics of intermittent induction and maintenance IV regimens.
|Study Design:||Primary Purpose: Treatment|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002272
|United States, Texas|
|Foscarnet Research Program / Park Plaza Hosp|
|Houston, Texas, United States, 77004|